340B Unscripted

Rob and Greg kick off the episode with some discussion around news and noteworthy items across the 340B landscape, including more dialogue around CMS guidance on “JG”/”TB” modifiers (1:01), 340B in the news media (4:31), grantee recertification tips (14:13) and ongoing challenges working 340B ESP (18:39). Later in the episode, they are joined by Victoria Ferris of OptumRx and Thatcher Sloan of RxBenefits to discuss pharmacy benefit strategy as an underappreciated opportunity in the 340B space (26:23).

For our last episode of 2022 Rob and Greg are joined again by SpendMend colleague Matt Parker and debate the top developments in the 340B space over the last year.

In this episode, we have podcast guests Anna Bulochnik, and Chelsea Violette to discuss the challenging task of switching third-party administrators (TPAs). Great tips and recommendations on how to make the transition as smooth as possible. 

On this episode, Rob and Greg welcome a few new SpendMend colleagues - Curtis McEntire and Angela Whitney– to talk about Trulla, a state-of-the-art pharmacy procurement solution now offered by SpendMend. They’ll talk about the challenges of today’s pharmacy buyer, common untapped opportunities for drug savings, and how Trulla can bring your pharmacy procurement process into the future.

It’s Halloween, and in this episode, Greg and Rob invite guests from the field to discuss “tricks and treats” from recent HRSA audit experiences! They’ll review strategies for gathering audit data, the coaching staff for the onsite visit, and what you need to consider when you eventually receive your final audit report. HRSA audits can be a “frightening” experience, but this conversation will give you lots of info to help you be ready! Also, the guys share updates on CMS OPPS payments for 340B hospitals.

In this episode, Rob and Gren welcome William Mayhood to the Pod and get into the New York Times article on Bon Secours’ 340B program. We shift gears and get into what covered entities should be doing in preparation for a similar media article, or congressional inquiry, and bring back the 340B Impact Statement. You never know, your CE could be next!

In this episode, Greg and Rob are joined by another SpendMend Pharmacy colleague – Riley Protz, who serves as Director of Optimization. They discuss the impact of referral capture opportunities on 340B Program participation and debate the risks of this strategy in comparison with other strategies, like the application of the “continuum of care” in the patient definition.